Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

por Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., Verweij, J.
Publicado 1996